Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Leases (2019 - 2025)

Rocket Pharmaceuticals' Current Leases history spans 7 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Current Leases rose 3.02% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, up 3.02%, while the annual FY2025 figure was $1.9 million, 3.02% up from the prior year.
  • Current Leases for Q4 2025 was $1.9 million at Rocket Pharmaceuticals, up from $1.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.9 million in Q4 2025 and bottomed at $634000.0 in Q3 2022.
  • The 5-year median for Current Leases is $1.1 million (2024), against an average of $1.2 million.
  • The largest annual shift saw Current Leases surged 130.36% in 2021 before it plummeted 62.19% in 2022.
  • A 5-year view of Current Leases shows it stood at $863000.0 in 2021, then dropped by 10.43% to $773000.0 in 2022, then increased by 19.66% to $925000.0 in 2023, then surged by 100.65% to $1.9 million in 2024, then increased by 3.02% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Current Leases are $1.9 million (Q4 2025), $1.0 million (Q2 2025), and $1.9 million (Q4 2024).